Serotonin-norepinephrine reuptake inhibitors in psychiatry and neurology

Sivolap Yu.P.

doi:https://doi.org/10.17116/jnevro2021121081141

Close metadata

Recommended articles:

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Investigation of the relationship of individual characteristics of the brain bioelectrical activity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117

Modern concepts of sleep disturbances associated with mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12

Validation of the Snaith—Hamilton Pleasure Scale to assess anhedonia in patients with unipolar depression In Russia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):110-121

Factors supporting chronic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

Gender characteristics of cardiovascular diseases psychosocial risk factors associations with sleep quality in an open urban population. Russian Journal of Preventive Medicine. 2025;(6):67-73

Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37

Abstract:

Antidepressants are one of the most important classes of psychotropic drugs and they are widely used in clinical practice, mainly in psychiatry and neurology. The main indications for the use of antidepressants are depression and anxiety disorders. First-line antidepressants are selective serotonin reuptake inhibitors, as well as serotonin-norepinephrine reuptake inhibitors which due to their dual pharmacological action have an additional effect on pain syndromes that determines their use in the treatment of neuropathic pain and fibromyalgia. A special place among the serotonin-norepinephrine reuptake inhibitors has duloxetine, which is characterized by proven efficacy in the treatment of depression, anxiety disorders, as well as isolated and comorbid pain. The optimal balance of efficacy and tolerability determines the possibility of safe use of duloxetine in patients with severe neurological disorders.

Keywords:

depression

anxiety disorders

neurological diseases

selective serotonin reuptake inhibitors

serotonin-norepinephrine reuptake inhibitors

duloxetine

Authors:

Sivolap Yu.P.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

06.07.2021

Accepted:

26.07.2021

Close metadata

References:

Pratt L.A., Brody D., Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011-2014. NCHS-Data-Brief, 2017; (283): 1-8.
Schatzberg A., DeBattista C. Schatzberg’s Manual of Clinical Psychopharmacology (Ninth Edition). — Washington: American Psychiatric Association Publishing, 2019. — 811 p.
Armitage R. Antidepressants, primary care, and adult mental health services in England during COVID-19. Lancet-Psychiatry, 2021; 8 (2): e3. https://doi.org/10.1016/S2215-0366(20)30530-7
Baandrup L. Polypharmacy in schizophrenia. Basic-Clin-Pharmacol-Toxicol, 2020; 126 (3): 183-192. https://doi.org/10.1111/bcpt.13384
Bosanac P., Castle D.J. Schizophrenia and depression. Med-J-Aust, 2013; 199 (S6): S36-39. https://doi.org/10.5694/mja12.10516
Kanner A.M. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia, 2013; 54 Suppl 1: 3-12. https://doi.org/10.1111/epi.12100
Konyushok M. Why neurologists should remember about antidepressants. European-J-Med-Healh-Sci, 2020; 2 (4): 2-5.
Cai W., Stewart R., Mueller C., Li Y.J., Shen W.D. Poststroke depression and risk of stroke recurrence and mortality: protocol of a meta-analysis and systematic review. BMJ-Open, 2018; 8 (12): e026316. https://doi.org/10.1136/bmjopen-2018-026316
Robinson R.G., Jorge R.E. Post-stroke depression: a review. Am-J-Psychiatry, 2016; 173 (3): 221-231. https://doi.org/10.1176/appi.ajp.2015.15030363
Alqdwah-Fattouh R., Rodríguez-Martín S., de Abajo F.J., González-Bermejo D., Gil M., García-Lledó A., Bolúmar F. Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case-control study. J-Clin-Pharmacol, 2020; 86(10): 2040-2050. https://doi.org/10.1111/bcp.14299
Burch R. Antidepressants for preventive treatment of migraine. Curr-Treat-Options-Neurol, 2019; 21 (4): 18. https://doi.org/10.1007/s11940-019-0557-2
Semple D., Smyth R. Oxford Handbook of Psychiatry (Fourth Edition). — Oxford: Oxford University Press, 2019. — 1148 p.
Coryell W. Drug Treatment of Depression. MSD MANUAL Professional Version, 2020. https://www.msdmanuals.com/professional/psychiatric-disorders/mood-disorders/drug-treatment-of-depression
Rizvi S.M.D., Shaikh S., Khan M., Biswas D., Hameed N., Shakil S. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. Neurol-Disord-Drug-Targets, 2014; 13 (8): 1427-1431. https://doi.org/10.2174/1871527313666141023145703
Dunner D.L., Goldstein D.J., Mallinckrodt M., Lu Y., Detke M.J. Duloxetine in treatment of anxiety symptoms associated with depression. Depress-Anxiety, 2003; 18 (2): 53-61. https://doi.org/10.1002/da.10122
Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., Tran P.V. Duloxetine for the treatment of major depressive disorder. Psychopharmacol-Bull, 2002; 36 (4): 106-132.
Chekroud A.M., Gueorguieva R., Krumholz H.M., Trivedi M.H., Krystal J.H., McCarthy G. Reevaluating the efficacy and predictability of antidepressant treatments: A symptom clustering approach. JAMA-Psychiatry, 2017; 74 (4): 370-378. https://doi.org/10.1001/jamapsychiatry.2017.0025
Sakurai H., Uchida H., Kato M., Suzuki T., Baba H., Watanabe K., Inada K., Kikuchi T., Katsuki A., Kishida I, Kikuchi Y.S., Yasui-Furukori N., Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological management of depression: Japanese expert consensus. J-Affect-Disord, 2020; 266: 626-632. https://doi.org/10.1016/j.jad.2020.01.149
Raskin J., Wiltse C.G., Siegal A., Sheikh J., Xu J., Dinkel J.J., Rotz B.T., Mohs R.C. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am-J-Psychiatry, 2007; 164 (6): 900-909. https://doi.org/10.1176/ajp.2007.164.6.900
Koponen H., Allgulander C., Erickson J., Dunayevich E., Pritchett Y., Detke M.J., Ball S.G., Russell J.M. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. J-Clin-Psychiatry, 2007; 9 (2): 100-107. https://doi.org/10.4088/pcc.v09n0203
Wernicke J.F., Pritchett Y.L., D’Souza D.N., Waninger A., Tran P., Iyengar S., Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 2006; 67 (8): 1411-1420. https://doi.org/10.1212/01.wnl.0000240225.04000.1a
Takahashi M., Tabu H., Ozaki A., Hamano T., Takeshima T. Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: A multicenter randomized study. Intern-Med, 2019; 58 (3): 361-368. https://doi.org/10.2169/internalmedicine.1359-18
Karaiskos D., Tzavellas E., Spengos K., Vassilopoulou S., Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J-Neuropsychiatry-Clin-Neurosci, 2012; 24 (3): 349-353. https://doi.org/10.1176/appi.neuropsych.11110325
Sun Y., Liang Y., Jiao Y., Lin J., Qu H., Xu J., Zhao C. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ-Open, 2017; 7 (8): e016499. https://doi.org/10.1136/bmjopen-2017-016499
Syed F., Herial N. Review of current pharmacotherapy for post-stroke depression (P3.3-022). Neurology, 2019, 92 (15 Supple): P3.3-022.
Solaro C., Bergamaschi R., Rezzani C., Muelle M., Trabucco E., Bargiggia V., Dematteis F., Mattioda A., Cimino V., Restivo D., Patti F., Cavalla P. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin-Neuropharmacol; 2013; 36 (4): 114-116. https://doi.org/10.1097/WNF.0b013e3182996400
Cozart B., Vera J.D., Denham J.D., Whiting W.L. Treatment of depression with duloxetine in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Clin-Neuropharmacol, 2018; 41 (3): 103-105. https://doi.org/10.1097/WNF.0000000000000277
Agüera-Ortiz L., García-Ramos R., Pérez F.J.G., López-Álvarez J., Rodríguez J.M.M., Rodríguez F.J.O., Pueyo J.O., Valero C.P., Porta-Etessam J. Focus on depression in Parkinson’s disease: A Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinsons-Dis, 2021; 2021: 6621991; https://doi.org/10.1155/2021/6621991
Agüera-Ortiz L., García-Ramos R., Pérez F.J.G., López-Álvarez J., Rodríguez J.M.M., Rodríguez F.J.O., Pueyo J.O., Valero C.P., Porta-Etessam J. Depression in Alzheimer’s disease: A Delphi consensus on etiology, risk factors, and clinical management. Front-Psychiatry, 2021 Feb 26;12:638651. https://doi.org/10.3389/fpsyt.2021.638651
Li J., Yang L., Pu P., Tang Y., Yun H., Han P. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int-Urol-Nephrol, 2013; 45 (3): 679-86. https://doi.org/10.1007/s11255-013-0410-6
Sartori S.B., Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol-Ther, 2019; 204: 107402. https://doi.org/10.1016/j.pharmthera.2019.107402